Fulvestrant + Neratinib In Breast Cancer

Clinical trial NCT04901299 · WITHDRAWN

Trial details

NCT number: NCT04901299
Sponsor: Massachusetts General Hospital
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Stage IV (Metastatic) Breast Cancer Metastatic Breast Cancer ER Positive Breast Cancer PR-Positive Breast Cancer HER2-negative Breast Cancer Invasive Breast Cancer

Start date: 2023-07-01
Primary completion: 2024-07-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.